JP2009525993A - 統合失調症の症状を治療または軽減するためにｋｃｎｑ開口薬を使用する方法 - Google Patents

統合失調症の症状を治療または軽減するためにｋｃｎｑ開口薬を使用する方法 Download PDF

Info

Publication number
JP2009525993A
JP2009525993A JP2008553621A JP2008553621A JP2009525993A JP 2009525993 A JP2009525993 A JP 2009525993A JP 2008553621 A JP2008553621 A JP 2008553621A JP 2008553621 A JP2008553621 A JP 2008553621A JP 2009525993 A JP2009525993 A JP 2009525993A
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
alkynyl
cycloalkenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2008553621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525993A5 (enExample
Inventor
フスムバク−イェンセン・ヘンリエッテ
ヴェンセル・トロネー・クリスティアン
ロットレンダー・マーリオ
グレーヴェ・ダニエル・ロドリグェス
カーンジン・ニコライ
リッツェン・アンドレアス
ワトソン・ウィリアム・パトリック
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38055396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009525993(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2009525993A publication Critical patent/JP2009525993A/ja
Publication of JP2009525993A5 publication Critical patent/JP2009525993A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008553621A 2006-02-07 2007-02-02 統合失調症の症状を治療または軽減するためにｋｃｎｑ開口薬を使用する方法 Ceased JP2009525993A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77130406P 2006-02-07 2006-02-07
DKPA200600175 2006-02-07
PCT/DK2007/050013 WO2007090409A1 (en) 2006-02-07 2007-02-02 Use of kcnq-openers for threating or reducing the symptoms of schizophrenia

Publications (2)

Publication Number Publication Date
JP2009525993A true JP2009525993A (ja) 2009-07-16
JP2009525993A5 JP2009525993A5 (enExample) 2010-03-25

Family

ID=38055396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008553621A Ceased JP2009525993A (ja) 2006-02-07 2007-02-02 統合失調症の症状を治療または軽減するためにｋｃｎｑ開口薬を使用する方法

Country Status (16)

Country Link
US (1) US20090118285A1 (enExample)
EP (2) EP2554162A1 (enExample)
JP (1) JP2009525993A (enExample)
KR (1) KR20080096659A (enExample)
CN (1) CN101378742B (enExample)
AR (1) AR059319A1 (enExample)
AU (1) AU2007214128B2 (enExample)
BR (1) BRPI0707495A2 (enExample)
CA (1) CA2641564C (enExample)
EA (1) EA017915B1 (enExample)
IL (1) IL192745A0 (enExample)
MX (1) MX2008009655A (enExample)
NO (1) NO20083838L (enExample)
NZ (1) NZ569517A (enExample)
TW (1) TWI453013B (enExample)
WO (1) WO2007090409A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
CA2804165C (en) 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
WO2016077724A1 (en) * 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
MA51881B1 (fr) 2018-02-20 2023-08-31 H Lundbeck As Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7
WO2019203951A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
RS66130B1 (sr) 2019-08-02 2024-11-29 H Lundbeck As Derivati alkohola kao otvarači kv7 kalijumovih kanala
CN119490430A (zh) 2019-08-02 2025-02-21 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
US20230015539A1 (en) * 2019-12-06 2023-01-19 Icahn School Of Medicine At Mount Sinai Method of treatment with kcnq channel openers

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05345752A (ja) * 1992-01-08 1993-12-27 Asta Medica Ag 新規の１，２，４−トリアミノベンゼン誘導体およびその製造方法
WO2002062295A2 (en) * 2001-02-02 2002-08-15 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
JP2003503447A (ja) * 1999-07-01 2003-01-28 グラクソ グループ リミテッド カリウムチャンネルオープナーの新規用途
US20030166650A1 (en) * 2001-05-31 2003-09-04 Yong-Jin Wu Cinnamide derivatives as KCNQ potassium channel modulators
US20040106621A1 (en) * 2002-11-22 2004-06-03 Yong-Jin Wu 3-Heterocyclic benzylamide derivatives as potassium channel openers
WO2004058739A1 (en) * 2002-12-27 2004-07-15 H. Lundbeck A/S 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
WO2004060880A1 (en) * 2002-12-20 2004-07-22 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as kcnq modulators
WO2004080377A2 (en) * 2003-03-11 2004-09-23 Neurosearch A/S Kcnq channel modulating compounds and their pharmaceutical use
WO2004080950A1 (en) * 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
WO2004082677A1 (en) * 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
WO2005025293A2 (en) * 2003-09-10 2005-03-24 Icagen, Inc. Fused ring heterocycles as potassium channel modulators
WO2005085276A1 (en) * 2004-02-20 2005-09-15 National Centre For Biological Sciences A novel potassium channel modulator peptide
WO2005087754A1 (en) * 2004-03-12 2005-09-22 H. Lundbeck A/S Substituted morpholine and thiomorpholine derivatives
WO2006029623A1 (en) * 2004-09-13 2006-03-23 H. Lundbeck A/S Substituted aniline derivatives
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4294142B2 (ja) 1999-02-02 2009-07-08 株式会社日立製作所 ディスクサブシステム
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
CA2438868A1 (en) * 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
WO2007063418A2 (en) * 2005-04-13 2007-06-07 Neuraxon, Inc. Substituted indole compounds having nos inhibitory activity

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05345752A (ja) * 1992-01-08 1993-12-27 Asta Medica Ag 新規の１，２，４−トリアミノベンゼン誘導体およびその製造方法
JP2003503447A (ja) * 1999-07-01 2003-01-28 グラクソ グループ リミテッド カリウムチャンネルオープナーの新規用途
WO2002062295A2 (en) * 2001-02-02 2002-08-15 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US20030166650A1 (en) * 2001-05-31 2003-09-04 Yong-Jin Wu Cinnamide derivatives as KCNQ potassium channel modulators
US20040106621A1 (en) * 2002-11-22 2004-06-03 Yong-Jin Wu 3-Heterocyclic benzylamide derivatives as potassium channel openers
WO2004060880A1 (en) * 2002-12-20 2004-07-22 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as kcnq modulators
WO2004058739A1 (en) * 2002-12-27 2004-07-15 H. Lundbeck A/S 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
WO2004080377A2 (en) * 2003-03-11 2004-09-23 Neurosearch A/S Kcnq channel modulating compounds and their pharmaceutical use
WO2004080950A1 (en) * 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
WO2004082677A1 (en) * 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
WO2005025293A2 (en) * 2003-09-10 2005-03-24 Icagen, Inc. Fused ring heterocycles as potassium channel modulators
WO2005085276A1 (en) * 2004-02-20 2005-09-15 National Centre For Biological Sciences A novel potassium channel modulator peptide
WO2005087754A1 (en) * 2004-03-12 2005-09-22 H. Lundbeck A/S Substituted morpholine and thiomorpholine derivatives
WO2006029623A1 (en) * 2004-09-13 2006-03-23 H. Lundbeck A/S Substituted aniline derivatives
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012033283; ＡＫＨＯＮＤＺＡＤＥＨ，Ｓ．　ｅｔ　ａｌ: 'Ｄｉａｚｏｘｉｄｅ　ｉｎ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｓｃｈｉｚｏｐｈｒｅｎｉａ：　ｎｏｖｅｌ　ａｐｐｌｉｃａｔｉｏｎ　ｏｆ　ｐｏｔａｓｓｉｕｍ　ｃｈａｎｎｅｌ　ｏｐｅｎｅｒｓ　ｉｎ　ｔｈｅ　ｔ' Ｊ　Ｃｌｉｎ　Ｐｈａｒｍ　Ｔｈｅｒ Ｖｏｌ．２７，　Ｎｏ．６, 2002, ｐ．４５３-９ *
JPN6012033287; ＺＨＡＮＧ，Ｌ．　ｅｔ　ａｌ: 'Ｐｏｓｓｉｂｌｅ　ｒｏｌｅ　ｏｆ　ｐｏｔａｓｓｉｕｍ　ｃｈａｎｎｅｌ，　ｂｉｇ　Ｋ　ｉｎ　ｅｔｉｏｌｏｇｙ　ｏｆ　ｓｃｈｉｚｏｐｈｒｅｎｉａ' Ｍｅｄ　Ｈｙｐｏｔｈｅｓｅｓ Ｖｏｌ．６７，　Ｎｏ．１, 2006, ｐ．４１-３ *
JPN6013008049; ＧＲＩＢＫＯＦＦ，Ｖ．Ｋ．: 'Ｔｈｅ　ｔｈｅｒａｐｅｕｔｉｃ　ｐｏｔｅｎｔｉａｌ　ｏｆ　ｎｅｕｒｏｎａｌ　ＫＣＮＱ　ｃｈａｎｎｅｌ　ｍｏｄｕｌａｔｏｒｓ' Ｅｘｐｅｒｔ　Ｏｐｉｎ　Ｔｈｅｒ　Ｔａｒｇｅｔｓ Ｖｏｌ．７，　Ｎｏ．６, 2003, ｐ．７３７-４８ *
JPN6013008052; ＣＺＡＰＩＮＳＫＩ，Ｐ．　ｅｔ　ａｌ: 'Ｍｅｃｈａｎｉｓｍｓ　ｏｆ　ａｃｔｉｏｎ　ｏｆ　ａｎｔｉｅｐｉｌｅｐｔｉｃ　ｄｒｕｇｓ' Ｃｕｒｒ　Ｔｏｐ　Ｍｅｄ　Ｃｈｅｍ Ｖｏｌ．５，　Ｎｏ．１, 2005, ｐ．３-１４ *

Also Published As

Publication number Publication date
EP2554162A1 (en) 2013-02-06
AR059319A1 (es) 2008-03-26
EA200870232A1 (ru) 2009-02-27
IL192745A0 (en) 2009-02-11
AU2007214128B2 (en) 2012-05-17
CN101378742B (zh) 2013-07-10
NZ569517A (en) 2011-07-29
EA017915B1 (ru) 2013-04-30
CN101378742A (zh) 2009-03-04
MX2008009655A (es) 2008-09-03
CA2641564C (en) 2012-06-12
TWI453013B (zh) 2014-09-21
US20090118285A1 (en) 2009-05-07
KR20080096659A (ko) 2008-10-31
TW200808296A (en) 2008-02-16
NO20083838L (no) 2008-10-31
BRPI0707495A2 (pt) 2011-05-03
EP1983974A1 (en) 2008-10-29
CA2641564A1 (en) 2007-08-16
AU2007214128A1 (en) 2007-08-16
WO2007090409A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
US20100256145A1 (en) Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
CA2641564C (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
US8299071B2 (en) Substituted pyridine derivatives
US20060199805A1 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
JP5907975B2 (ja) 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
JP2018516992A (ja) レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
US20140243350A1 (en) Use of serotonin receptor agonists for treatment of movement disorders
EP3400940B1 (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
HK1181676A (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
HK1129593B (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia
HK1129593A1 (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia
HK1146655A (en) Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
HK40000275B (en) Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100127

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100519

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120208

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130823

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130917

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140128